News >

AR-V7 Predicts Response in Castration-Resistant Prostate Cancer

Jason Harris
Published: Wednesday, Apr 12, 2017

Emmanuel S. Antonarakis, MD

Emmanuel S. Antonarakis, MD

The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies (NHT), according to results recently published in the Journal of Clinical Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication